Annalise Enterprise CXR Triage Trauma

Annalise Enterprise CXR Triage Trauma is an artificial intelligence software tool that utilizes a deep-learning convolutional neural network to analyze adult chest X-rays for pleural effusion and pneumoperitoneum, aiming to prioritize these studies in clinical worklists. The device integrates with existing hospital information systems (PACS/RIS) and has demonstrated high sensitivity and specificity in identifying these critical findings, thereby facilitating expedited radiological review.

Annalise Enterprise CXR Triage Trauma is an AI-driven software tool designed to assist clinicians in prioritizing adult chest X-ray (CXR) studies by analyzing them for features suggestive of pleural effusion and pneumoperitoneum. It integrates with existing Picture Archiving and Communication Systems (PACS) or Radiology Information Systems (RIS) to flag these cases for earlier review in the worklist, employing a convolutional neural network trained on diverse international datasets to identify these specific findings; the system operates in parallel with standard clinical workflows, aiming to enhance triage efficiency without altering existing case priorities or serving as a standalone diagnostic tool. The core technology's performance was validated through a standalone study on 1269 CXR cases, independent of its training data and benchmarked against US board-certified radiologists, which demonstrated high diagnostic accuracy with an Area Under the Curve (AUC) of 0.980 for pleural effusion and 0.969 for pneumoperitoneum. Specific operating points showed high sensitivity and specificity for both conditions (e.g., pleural effusion: 96.0% sensitivity, 88.3% specificity; pneumoperitoneum: 90.1% sensitivity, 87.4% specificity), and the device achieved an average triage turn-around time under 30 seconds, though performance limitations are noted for prone positioning, unilateral left-sided pneumoperitoneum, and pleural effusion cases with scarring or pleural thickening.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How does the algorithm's performance vary with different severities or subtle presentations of pleural effusion and pneumoperitoneum?; What specific image preprocessing steps are employed by the AI before analysis, and how do these impact its robustness to variations in image quality or acquisition parameters?; Given the stated limitation for unilateral left-sided pneumoperitoneum, what is the proposed strategy or future development plan to improve its detection accuracy for this specific presentation?; How does the device's performance compare when using CXRs from portable versus fixed X-ray units, considering potential differences in image quality and patient positioning challenges?; What is the false positive notification rate in a real-world clinical setting, and what are the most common benign findings that trigger false alerts for pleural effusion or pneumoperitoneum?